arrow_back Trending Legislation
Share share

Expanding Incentives for Valley Fever Drug Development.

This bill expands the Priority Review Voucher program to include Coccidioidomycosis (Valley Fever), a fungal infection. By adding this disease, the law aims to incentivize pharmaceutical companies to accelerate the development of new treatments and preventive measures. This change could lead to faster availability of effective therapies for citizens affected by this often-neglected condition.
Key points
Coccidioidomycosis (Valley Fever) is added to the list of diseases eligible for the Priority Review Voucher program.
The goal is to encourage pharmaceutical companies to develop treatments and prevention methods for this fungal infection more quickly.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Print number: S 3220
Sponsor: Sen. Kelly, Mark [D-AZ]
Process start date: 2023-11-02
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Expanding Incentives for Valley Fever Drug Development.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 3220.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-11-02.

What are the main provisions?

Key points include:

  • Coccidioidomycosis (Valley Fever) is added to the list of diseases eligible for the Priority Review Voucher program.
  • The goal is to encourage pharmaceutical companies to develop treatments and prevention methods for this fungal infection more quickly.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kelly, Mark [D-AZ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Analysis and Potential Impact of S 3220

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health